FatrixGel

FATRIXGEL provides a high-fidelity solution to the predictive gap in drug discovery through human-derived decellularized adipose extracellular matrix (hDAM) hydrogels. Unlike current mouse-tumor-derived standards such as Matrigel, FATRIXGEL offers an authentic human biomimetic microenvironment with guaranteed batch-to-batch consistency. This technological edge significantly accelerates critical cellular differentiation processes and enhances the reliability of in vitro disease models for sectors such as oncology and neural engineering.

Targeting the rapidly expanding Research Use Only (RUO) market, FATRIXGEL is available in highly processable formats—including pregels, bio-inks for 3D bioprinting, and porous scaffolds. With protected intellectual property and technical validation that meets strict international purity standards, including DNA levels below 50 ng/mg and endotoxins under 10 EU/mL, the project is positioned as an essential tool for the transition toward personalized medicine. By reducing clinical trial failure rates and minimizing reliance on animal models, FATRIXGEL offers a scalable, high-impact opportunity to redefine the future of biomedical research